Hims & Hers Health, Inc. has unveiled its second-quarter performance for 2026, showcasing a period of robust expansion and strategic technological integration. The company's focus on an AI-driven infrastructure, coupled with an aggressive international growth strategy, has positioned it as a significant player in the digital health sector. Key financial indicators reveal substantial year-over-year growth in revenue and subscriber numbers, alongside strategic investments designed to enhance customer experience and operational efficiency.
The company's Co-Founder and CEO, Andrew Dudum, along with CFO Yemi Okupe and CTO Mohamed ElShenawy, presented the financial outcomes and strategic direction during the earnings call on Monday, August 10, 2026. A central theme of their discussion was the transformative role of Artificial Intelligence in reshaping healthcare delivery. ElShenawy detailed how the new AI-native platform is not merely an add-on but a fundamental shift in customer engagement, particularly highlighted by its successful rollout in Hers' weight loss program. This initiative has led to a threefold increase in patient-platform interactions and a nearly 50% reduction in non-clinical support tasks, signaling improved efficiency and deeper patient involvement.
Dudum further elaborated on the company's commitment to creating a comprehensive health experience that is both accessible and personalized. He stressed that Hims & Hers' unique advantage lies in its end-to-end patient relationship, which generates invaluable data. This data, accumulated over nine years, informs the platform's AI, enabling it to provide tailored care and improve treatment outcomes across various specialties. The acquisition of Eucalyptus has significantly bolstered the company's international reach, establishing a global platform that provides integrated care solutions.
Financially, Hims & Hers reported a total revenue of $753.2 million, marking a 38% increase from the previous year, driven by product diversification and a growing subscriber base that reached nearly 3 million. Despite a net loss of $86.3 million, largely due to non-recurring costs associated with acquisitions and legal contingencies, the adjusted EBITDA stood at $60.3 million, achieving an 8% margin. The company also announced a reinforced balance sheet with a new $400 million receivables facility and a $400 million convertible debt offering to support its long-term growth ambitions. This includes expanding into new complex health categories such as testosterone replacement therapy and peptide offerings, with a clear vision to make high-quality, proactive healthcare affordable and globally accessible.
Looking ahead, Hims & Hers projects a strong finish to 2026, with revenue guidance of $3.1 billion to $3.3 billion and adjusted EBITDA of $275 million to $325 million for the full year. The company is actively investing in AI talent and infrastructure, including a new AI R&D lab in Menlo Park, anticipating that these investments will yield substantial returns within 12 to 18 months through enhanced customer retention and reduced operational costs. This strategic reinvestment aims to make healthcare more affordable for consumers while accelerating growth in key international markets where the adoption of health solutions, particularly weight loss, is rapidly increasing. The leadership remains confident in achieving its 2030 financial targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, solidifying its position as an innovator in consumer health.
